Compound Evidence File
#EC-2026-0803
GW-501516 (Cardarine)
Filed under Oral Tablets. The bureau holds 131 laboratory returns for this compound from 50 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
50 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 7 May 2026 | 10 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 21 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Nov 2025 | 3 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Feb 2026 | 6 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Dec 2025 | 25 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 8 Mar 2026 | 12 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 11 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 28 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Apr 2026 | 20 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 10.0 | 10.0 | 17 Mar 2026 | 22 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 10.0 | 10.0 | 10 May 2026 | 12 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Jan 2026 | 12 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Jul 2026 | 26 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Jul 2026 | 12 Aug 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 10.0 | 10.0 | 10.0 | 20 Jun 2025 | 20 Jun 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jan 2026 | 11 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Mar 2026 | 13 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 24 Dec 2025 | 9 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 8 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Nov 2025 | 6 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Jul 2026 | 14 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 2 May 2026 | 10 Jul 2026 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 9.6 | 9.6 | 9.6 | 2 Apr 2025 | 2 Apr 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.9 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 8.9 | 8.9 | 8.9 | 3 Jul 2025 | 3 Jul 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.8 | 7.5 | 10.0 | 23 May 2026 | 23 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.8 | 8.8 | 8.8 | 7 May 2025 | 7 May 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 8.7 | 8.1 | 9.3 | 24 May 2026 | 24 May 2026 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 8.7 | 8.7 | 8.7 | 16 Mar 2025 | 16 Mar 2025 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 8.5 | 8.5 | 8.5 | 21 May 2025 | 21 May 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.3 | 8.1 | 8.7 | 24 May 2026 | 24 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 8.2 | 8.2 | 8.2 | 27 Feb 2025 | 27 Feb 2025 |
| Henan Sahe PeptideCASE #VI-2026-0894 | X | 1 | 8.2 | 8.2 | 8.2 | 21 May 2025 | 21 May 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.1 | 7.2 | 10.0 | 25 May 2026 | 25 May 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 8.0 | 8.0 | 8.0 | 2 Apr 2025 | 2 Apr 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 7.8 | 7.8 | 7.8 | 3 Jun 2025 | 3 Jun 2025 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 7.8 | 7.8 | 7.8 | 8 Jul 2025 | 8 Jul 2025 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 7.6 | 7.6 | 7.6 | 3 Jun 2025 | 3 Jun 2025 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 1 | 6.4 | 6.4 | 6.4 | 8 Jul 2025 | 8 Jul 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 3 | 6.0 | 5.3 | 6.7 | 2 Apr 2025 | 26 Jan 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 5.9 | 5.9 | 5.9 | 17 Dec 2024 | 17 Dec 2024 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 1 | 5.4 | 5.4 | 5.4 | 21 May 2025 | 21 May 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 1 | 5.3 | 5.3 | 5.3 | 2 Apr 2025 | 2 Apr 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 2 | 4.8 | 2.2 | 7.4 | 3 Jul 2025 | 24 May 2026 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 1 | 4.8 | 4.8 | 4.8 | 11 Jun 2025 | 11 Jun 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 4.7 | 4.7 | 4.7 | 9 Jun 2025 | 9 Jun 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 4.1 | 4.1 | 4.1 | 13 Jun 2025 | 13 Jun 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.2 | 0.2 | 0.2 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for GW-501516 (Cardarine) alone.